Seeking Investors: First-in-Class Immunotherapeutics for Cancer
ATLANTA, Jan. 27, 2025 /PRNewswire/ -- Cambium Oncology is pleased to share that their lead drug candidate, ANT308, recently demonstrated outstanding single-agent efficacy and safety in preclinical studies. The drug is mutation-agnostic, and the company observes no toxicity-limiting dosages. In addition to their Fast-Track SBIR NIH grant recently being funded for $2.4M,...
CStone Partners with SteinCares to Market Sugemalimab in Latin America
CStone will receive upfront, regulatory and commercial milestone payments, and book revenue from SteinCares through the supply of sugemalimab in 10 Latin American (LATAM) countries. This marks CStone's third major global commercialization partnership for sugemalimab, with additional deals in Western Europe, Southeast Asia, Canada, and other regions anticipated soon. CStone has received marketing approval for sugemalimab in the...
Arab Health 2025｜Yuwell Medical Announces Strategic Investment and Partnership with Inogen in Respiratory Health
DUBAI, UAE, Jan. 27, 2025 /PRNewswire/ -- On the eve of the Arab Health Exhibition, Yuwell Medical held its 2025 Global Core Partner Conference in Dubai, and announced a strategic investment and partnership with Inogen, a leading U.S. company in respiratory health, highlighting our joint commitment to advancing medical device solutions and deeper collaboration. Alex WU, Chairman of Yuwell Medical,...
Akeso’s Gumokimab Monoclonal Antibody (IL-17) New Drug Application for the Treatment of Moderate to Severe Psoriasis Accepted by NMPA
HONG KONG, Jan. 27, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") is pleased to announce that the New Drug Application (NDA) of its internally-developed IL-17-targeting monoclonal antibody gumokimab (AK111) has been accepted by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) for the treatment of moderate to severe plaque psoriasis....
CARiNG Pharmacy Celebrates Consecutive Gold Triumph at the 2024 Putra Aria Brand Awards
KUALA LUMPUR, Malaysia, Jan. 27, 2025 /PRNewswire/ -- CARiNG Pharmacy is thrilled to announce its back-to-back victory in securing the Gold award in the retail category at the 2024 Putra Aria Brand Awards. This recognition highlights the brand's unwavering commitment to excellence in the retail sector. Established in 2022 by the Association of Accredited Advertising Agents Malaysia (4As), the...
Alpro Pharmacy and OMRON Healthcare Unite to Combat Fake BP Monitors
Free Blood Pressure Monitor Accuracy Check Nationwide KUALA LUMPUR, Malaysia, Jan. 27, 2025 /PRNewswire/ -- Hypertension, or high blood pressure, affects 3 in 10 Malaysians, making it a prevalent health concern in the country (National Health and Morbidity Survey, 2019). Of the 3, only 2 are aware of their condition, while the other remains undiagnosed, highlighting a critical gap...
FDA Clears World’s First Mobile App for Contactless Pulse Rate Measurement
PanopticAI's tech turns smartphones and tablets into medical-grade vital sign monitors. This is a major milestone in the Hong Kong-based startup's mission to ensure accessible, scalable healthcare. The AI-based technology's diverse use cases include telehealth, remote patient monitoring, community health screening, decentralized clinical trials and personal wellness. PanopticAI's early adopters include Gleneagles Hospital Hong Kong (part of IHH...
Sasakawa Leprosy Initiative to Boost Support for Indonesia
Yohei Sasakawa, WHO Goodwill Ambassador for Leprosy Elimination, Makes Announcement on World Leprosy Day 2025 TOKYO, Jan. 25, 2025 /PRNewswire/ -- On the occasion of World Leprosy Day 2025 on January 26, WHO Goodwill Ambassador for Leprosy Elimination Yohei Sasakawa announces that the Sasakawa Leprosy Initiative (SLI) will increase its support to Indonesia to combat the stigma and discrimination associated with...
X4 Pharmaceuticals Announces EMA Validation of Marketing Authorization Application (MAA) for Mavorixafor – licenced to Norgine for commercialisation in Europe.
LONDON, Jan. 25, 2025 /PRNewswire/ -- Following the licensing agreement with X4 Pharmaceuticals, Norgine is pleased to see the announcement from X4 today that their Marketing Authorization Application (MAA) for mavorixafor for the treatment of WHIM syndrome (warts, hypogammaglobulinemia, infections and myelokathexis), a rare primary immunodeficiency, has been validated for review and...
Clarity receives U.S. FDA Fast Track Designation for Cu-64 SAR-bisPSMA in biochemical recurrence of prostate cancer
SYDNEY, Jan. 24, 2025 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity" or "Company"), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for children and adults with cancer, is pleased to announce that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation (FTD)...
